Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
34.72 (1y: +39%)
Market Cap 973.4 M P/E(ttm) 27.60
Enterprise Value 741.45 M P/B 2.70
ARTC- NAS (USA)
ArthroCare Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$34.72
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry		 vs
history
Cash to Debt No Debt
ARTC's Cash to Debt is ranked higher than
60% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3750.67 vs. ARTC: No Debt )
ARTC' s 10-Year Cash to Debt Range
Min: 0.69   Max: No Debt
Current: No Debt
Equity to Asset 0.466
ARTC's Equity to Asset is ranked lower than
58% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.53 vs. ARTC: 0.466 )
ARTC' s 10-Year Equity to Asset Range
Min: 0.26   Max: 0.94
Current: 0.47
0.26
0.94
Interest Coverage 75.6
ARTC's Interest Coverage is ranked higher than
65% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 420.30 vs. ARTC: 75.6 )
ARTC' s 10-Year Interest Coverage Range
Min: 34   Max: No Debt
Current: 75.6
F-Score: 5
Z-Score: 5.78
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating margin (%) 17.40
ARTC's Operating margin (%) is ranked higher than
78% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. ARTC: 17.40 )
ARTC' s 10-Year Operating margin (%) Range
Min: -16.1   Max: 17.4
Current: 17.4
-16.1
17.4
Net-margin (%) 12.6
ARTC's Net-margin (%) is ranked higher than
78% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. ARTC: 12.6 )
ARTC' s 10-Year Net-margin (%) Range
Min: -17.7   Max: 17.1
Current: 12.6
-17.7
17.1
ROE (%) 12.7
ARTC's ROE (%) is ranked higher than
75% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 4.80 vs. ARTC: 12.7 )
ARTC' s 10-Year ROE (%) Range
Min: -14.9   Max: 12.7
Current: 12.7
-14.9
12.7
ROA (%) 8.9
ARTC's ROA (%) is ranked higher than
76% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. ARTC: 8.9 )
ARTC' s 10-Year ROA (%) Range
Min: -10.9   Max: 9.6
Current: 8.9
-10.9
9.6
ROC (Joel Greenblatt) (%) 64.50
ARTC's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 14.00 vs. ARTC: 64.50 )
ARTC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -39.8   Max: 64.5
Current: 64.5
-39.8
64.5
Revenue Growth (%) 1.2
ARTC's Revenue Growth (%) is ranked higher than
72% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ARTC: 1.2 )
ARTC' s 10-Year Revenue Growth (%) Range
Min: 1.2   Max: 19.5
Current: 1.2
1.2
19.5
EBITDA Growth (%) 36
ARTC's EBITDA Growth (%) is ranked lower than
75% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. ARTC: 36 )
ARTC' s 10-Year EBITDA Growth (%) Range
Min: -21.5   Max: 58.4
Current: 36
-21.5
58.4
ยป ARTC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ARTC Guru Trades in Q2 2012

Steven Cohen 114,519 sh (+635.32%)
Paul Tudor Jones 250,000 sh (+94.86%)
Jim Simons 474,000 sh (+19.25%)
Joel Greenblatt 73,539 sh (+1.96%)
Mario Gabelli 384,800 sh (+0.52%)
George Soros 50,000 sh (unchged)
» More
Q3 2012

ARTC Guru Trades in Q3 2012

Steven Cohen 400,300 sh (+249.55%)
George Soros Sold Out
Mario Gabelli 373,300 sh (-2.99%)
Jim Simons 404,500 sh (-14.66%)
Paul Tudor Jones 175,000 sh (-30%)
Joel Greenblatt 36,588 sh (-50.25%)
» More
Q4 2012

ARTC Guru Trades in Q4 2012

Steven Cohen 1,538,875 sh (+284.43%)
Jim Simons 439,129 sh (+8.56%)
Mario Gabelli 352,800 sh (-5.49%)
Paul Tudor Jones 100,000 sh (-42.86%)
Joel Greenblatt 19,359 sh (-47.09%)
» More
Q1 2013

ARTC Guru Trades in Q1 2013

Joel Greenblatt 38,119 sh (+96.91%)
Paul Tudor Jones 127,600 sh (+27.6%)
Jim Simons 450,718 sh (+2.64%)
Mario Gabelli 336,600 sh (-4.59%)
Steven Cohen 1,126,846 sh (-26.77%)
» More
» Details

Insider Trades

Latest Guru Trades with ARTC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Add 96.91%0.03%$34.59 - $36.88 $ 34.72-3%38119
Joel Greenblatt 2012-12-31 Reduce -47.09%0.04%$29.73 - $34.09 $ 34.727%19359
Joel Greenblatt 2012-09-30 Reduce -50.25%0.08%$27.35 - $32.4 $ 34.7217%36588
George Soros 2012-09-30 Sold Out 0.02%$27.35 - $32.4 $ 34.7217%0
Joel Greenblatt 2012-03-31 Add 58.88%0.06%$24.74 - $32.52 $ 34.7232%72128
George Soros 2012-03-31 Reduce -31.46%0.03%$24.74 - $32.52 $ 34.7232%50000
Joel Greenblatt 2011-12-31 Add 24.38%0.03%$25.56 - $31.84 $ 34.7219%45398
Joel Greenblatt 2011-09-30 Add 101.04%0.09%$27.98 - $34.77 $ 34.7210%36498
George Soros 2011-09-30 Reduce -45.16%0.03%$27.98 - $34.77 $ 34.7210%77052
John Hussman 2011-06-30 Sold Out $32.31 - $35.33 $ 34.723%0
John Hussman 2011-03-31 Reduce -51.18%0.27%$27.82 - $35.27 $ 34.7211%476000
Joel Greenblatt 2011-03-31 New Buy0.17%$27.82 - $35.27 $ 34.7211%16645
George Soros 2011-03-31 New Buy0.06%$27.82 - $35.27 $ 34.7211%141304
Mario Gabelli 2011-03-31 Reduce -35.82%0.06%$27.82 - $35.27 $ 34.7211%440000
George Soros 2010-09-30 Sold Out 0.01%$25.21 - $29.21 $ 34.7228%0
George Soros 2010-06-30 New Buy0.01%$26.31 - $32.18 $ 34.7214%8500
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about ArthroCare Corporation

Steven Cohen Significantly Increases in ArthroCare Corp., Almost 300%
December 3, 2012
Steven Cohen - Steven Cohen Significantly Increases In ArthroCare Corp., Almost 300%
As of Nov. 29, billionaire Guru investor, Steven Cohen, founder of SAC Capital Advisors, has reported to purchasing more than 1.5 million shares of ArthroCare Corp. (ARTC), increasing his holding by 288.73 percent according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 27.60
ARTC's P/E(ttm) is ranked higher than
64% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. ARTC: 27.60 )
ARTC' s 10-Year P/E(ttm) Range
Min: 18.36   Max: 272.5
Current: 27.6
18.36
272.5
P/B 2.70
ARTC's P/B is ranked lower than
62% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. ARTC: 2.70 )
ARTC' s 10-Year P/B Range
Min: 0.37   Max: 12.7
Current: 2.7
0.37
12.7
P/S 2.70
ARTC's P/S is ranked lower than
67% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ARTC: 2.70 )
ARTC' s 10-Year P/S Range
Min: 0.28   Max: 22.35
Current: 2.7
0.28
22.35
PFCF 14.10
ARTC's PFCF is ranked lower than
82% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 18.60 vs. ARTC: 14.10 )
ARTC' s 10-Year PFCF Range
Min: 5.79   Max: 895
Current: 14.1
5.79
895
EV-to-EBIT 12.3
ARTC's EV-to-EBIT is ranked higher than
80% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 16.25 vs. ARTC: 12.3 )
ARTC' s 10-Year EV-to-EBIT Range
Min: 9.8   Max: 950.9
Current: 12.3
9.8
950.9
Shiller P/E 152.5
ARTC's Shiller P/E is ranked higher than
76% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 23.60 vs. ARTC: 152.5 )
ARTC' s 10-Year Shiller P/E Range
Min: 13.04   Max: 2750
Current: 152.5
13.04
2750

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 15.4
ARTC's Price/Net Cash is ranked higher than
94% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 12.00 vs. ARTC: 15.4 )
ARTC' s 10-Year Price/Net Cash Range
Min: 7   Max: 163.3
Current: 15.4
7
163.3
Price/Net Current Asset Value 15.4
ARTC's Price/Net Current Asset Value is ranked higher than
79% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 8.90 vs. ARTC: 15.4 )
ARTC' s 10-Year Price/Net Current Asset Value Range
Min: 2.3   Max: 21.2
Current: 15.4
2.3
21.2
Price/Tangible Book 4
ARTC's Price/Tangible Book is ranked higher than
72% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. ARTC: 4 )
ARTC' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 10.2
Current: 4
1.2
10.2
Price/DCF (Projected) 1.7
ARTC's Price/DCF (Projected) is ranked higher than
89% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. ARTC: 1.7 )
ARTC' s 10-Year Price/DCF (Projected) Range
Min: 0.3   Max: 14.8
Current: 1.7
0.3
14.8
Price/Median PS Value 0.7
ARTC's Price/Median PS Value is ranked higher than
64% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. ARTC: 0.7 )
ARTC' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 1.8
Current: 0.7
0.1
1.8
Price/Graham Number 2
ARTC's Price/Graham Number is ranked higher than
81% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. ARTC: 2 )
ARTC' s 10-Year Price/Graham Number Range
Min: 2   Max: 4.3
Current: 2
2
4.3
Earnings Yield (Greenblatt) 8.10
ARTC's Earnings Yield (Greenblatt) is ranked higher than
88% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.95 vs. ARTC: 8.10 )
ARTC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 10.2
Current: 8.1
0.1
10.2
Forward Rate of Return (Yacktman) 2.23
ARTC's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. ARTC: 2.23 )
ARTC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.8   Max: 23.4
Current: 2.23
-0.8
23.4

Business Description

ArthroCare was incorporated in California in 1993 and reincorporated in Delaware in 1995. The Company is a multi-business medical device Company that develops, manufactures and markets minimally invasive surgical products, many of which are based on its patented Coblation(r) technology. The Company has grown well beyond its roots in arthroscopy to capitalize on numerous market opportunities across several medical specialties, improving many existing soft-tissue surgical procedures and enabling new minimally invasive procedures. With its innovative technologies, the Company is improving the lives of individuals suffering from conditions as diverse as torn rotator cuffs and anterior cruciate ligaments to herniated discs and enlarged tonsils/tonsillitis. The Company currently markets minimally invasive surgical products across three core business units-ArthroCare Sports Medicine, which include shoulder and knee arthroscopic products; ArthroCare Spine, which include spinal and neurosurgery products; and ArthroCare Ear, Nose and Throat, which include ear, nose, throat and the Visage(r) cosmetic products; - but also has developed, manufactured and marketed Coblation-based and complementary products for application in neurology, cosmetic surgery, urology and gynecology, with research continuing in additional areas. In each of its core business units, the Company is focusing on driving the application of enabling technologies, primarily for plasma-based soft tissue removal, and increasing the number of minimally invasive procedures being performed. The Company is marketing and selling its arthroscopic/sports medicine, spinal surgery, ENT and cosmetic surgery products using a combination of distributors supported by regional sales mangers, a direct sales force and corporate partners to sell its products both domestically and internationally. The Company owns over 170 issued U.S. patents and over 195 issued international patents. The Company's products are considered medical devices and are subject to regulation in the United States, with the approval of FDA for each of its products. Its primary competitors include Medtronic, Inc., Smith & Nephew, Stryker Corporation, Johnson & Johnson, Olympus (through its subsidiary Gyrus) and Arthrex, Inc.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
ยป More Articles for ARTC

Headlines

Articles On GuruFocus.com
Steven Cohen Significantly Increases in ArthroCare Corp., Almost 300% Dec 03 2012 
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Stryker Corp. (SYK) Dividend Stock Analysis Dec 16 2011 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 07 2010 
Guru Stocks at 52-Week Low: Genzyme Corp, ArthroCare Corp, Ticketmaster. Nov 30 2008 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial